Sign inCreate account

Report workspace tools

NCT03751007COMPLETEDanonymous

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

Sponsor

Source record

Precigen Actobio T1D, LLC

Phase

Source record

Phase 1b/2a

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Type 1 Diabetes (T1D)

Indication / condition

AI-normalized

Diabetes type1

Intervention

Source record

AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose, AG019 - High Dose

Source & freshness

Source record

NCT ID

NCT03751007

Original source

ClinicalTrials.gov

Source last updated

Feb 01, 2023

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03751007

Title

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

Sponsor

Precigen Actobio T1D, LLC

Status

COMPLETED

Phase

Phase 1b/2a

Condition raw

Diabetes type1

Condition normalized

Diabetes type1

Modality raw

Diabetes type1

Modality normalized

monoclonal antibody

Target raw

Type 1 Diabetes (T1D)

Target normalized

Type 1 Diabetes (T1D)

Interventions

AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose, AG019 - High Dose

Public preview

Source record

The clinical trial assessed the safety and tolerability of AG019, both as a monotherapy and in combination with Teplizumab, in patients with recent-onset Type 1 Diabetes. Conducted by Precigen Actobio T1D, LLC, the study aimed to evaluate different dosing regimens across two age groups (12-17 and 18-40 years).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03751007

Status

COMPLETED

Phase

Phase 1b/2a

Sponsor

Precigen Actobio T1D, LLC

Executive brief

Investment-Ready Snapshot

The clinical trial assessed the safety and tolerability of AG019, both as a monotherapy and in combination with Teplizumab, in patients with recent-onset Type 1 Diabetes. Conducted by Precigen Actobio T1D, LLC, the study aimed to evaluate different dosing regimens across two age groups (12-17 and 18-40 years).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 01, 2023
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03751007

Indication

Diabetes type1

Modality

monoclonal antibody

Target

Type 1 Diabetes (T1D)

Intervention

AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose, AG019 - High Dose

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.